-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bile tube cancer (BTC) is a rare gastrointestinal malignancies with poor prognosmation and often accompanied by inflammation.
Andersen et al. assessed the prognosmative value of IL6 and YKL-40 and CA19-9 before and after palliative chemotherapy, and studied in mice whether IL6R inhibition combined gissethamin could prolong the chemotherapy sensitivity period.
the study included 452 late-stage (locally late-stage or metastasis) BTC Danish patients in six clinical trials (2004-2017).
levels of serum CA199, IL6 and YKL-40 were detected before and after palliative chemotherapy.
the correlation between candidate biomarkers and progressive survival (PFS) and overall survival (OS) was analyzed using single-variable and multivariable Cox models.
in patients with advanced BTC, ca199, IL6, and YKL-40 pre-treatment high levels and elevated levels during treatment were associated with shorter PFS and OS.
IL6 provides independent prognossis information, independent of tumor location and serum CA199 levels.
ROC analysis shows that IL6 and YKL-40 can predict very short OS (-lt;6 months), while CA199 is best suited to predict OS in patients with OS over 1.5 years.
in BTC's transplanted tumor mouse model, the use of anti-IL6R combined gixitrabin therapy significantly slowed tumor growth compared to gixitrabin monotherapy.
, serum IL6 and YKL-40 are potential new prognosmical biomarkers for bile tube cancer.
IL6 provides independent prognosm information and may be superior to CA199.
addition, consideration should be given to anti-IL6R as a new treatment option to maintain the sensitivity of BTC patients to Gissitham treatment.
.